-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 17, Cansino released the 2021 semi-annual performance forecast.
In February 2021, the State Food and Drug Administration has conditionally approved CanSino’s application for the registration of the adenovirus vector new crown vaccine.
Judging from the disclosed report for the first quarter of 2021, although the sales time is relatively short, the new crown vaccine still helped CanSino achieve a revenue of about 467 million yuan, more than 1,100 times the same period last year, and a net loss of 14.
In addition, it is worth mentioning that, in addition to Cansino, China Biopharmaceuticals previously disclosed its financial report for the first quarter of 2021.